Thymosin Beta-4

See source wording

for 10 days

A Phase 1b Study of Thymosin Beta 4 in Healthy VolunteersPHASE1 · NCT04555850

“Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg ..”

See source wording

into a vein · daily

Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial InfarctionPHASE2 · NCT07586865

“It is supplied as a 1.5 mg (1 mL) vial and stored at 2-8°C.”

See source wording

into a vein · daily · for 3 days

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionPHASE2 · NCT01311518

“Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks.”

See source wording

into a vein

A Phase 1a Study of Thymosin Beta 4 in Healthy VolunteersPHASE1 · NCT04555824

“Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1..”

See source wording

into a vein · for 7 days

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionPHASE2 · NCT05485818

“12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）.”

See source wording

once a day

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersPHASE1 · NCT00743769

“Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4.”

See source wording

into a vein · for 7 days

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial InfarctionPHASE2 · NCT05984134

“Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days..”

See source wording

mice · once daily · for 6 days

Thymosin beta 4 prevents systemic lipopolysaccharide-induced plaque load in middle-age APP/PS1 mice.International immunopharmacology · 2023

“12.5-month-old male APP/PS1 mice (n = 30) and their WT littermates (n = 29) were tested for baseline food burrowing performance, spatial working memory and exploratory drive in the spontaneous alternation and open-field tests, prior to being challenged with LPS (100ug/kg, i.v.) or its vehicle phosphate buffered saline (PBS).”

6 mg/kg

mice · another route

Thymosin beta-4 prenatal administration improves fetal development and halts side effects due to preterm delivery.European review for medical and pharmacological sciences · 2021

“on day E14 and E17 of gestation mice were weighed and treated with an intraperitoneal injection of TB4 (Regene RX, Rockville, MD, USA; 6 mg/kg in PBS).”

5 mcg/ml

rats ·

[Effect and mechanism of thymosin beta 4 on spinal cord-derived neural stem /progenitor cell injury induced by oxidative stress].Zhongguo gu shang = China journal of orthopaedics and traumatology · 2022

“Methods NSPCs were isolated from Sprague-Dawley (SD) adult male rats, and divided into control group (untreated NSPCs cells), H 2 O 2 group (NSPCs cells damaged by 500 μM H 2 O 2 ), Tβ4 -3 groups (NSPCs were treated with 1, 2.5, 5 μg/ml Tβ4 on the basis of H 2 O 2 treatment) and TAK-242 group [NSPCs were treated with 5 μg/ml Tβ4 and Toll-like receptor 4(TLR4) inhibitor TAK-242 on the basis of H 2 O 2 treatment].”

600 ng

mice ·

Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells.Stem cell research & therapy · 2022

“We found that 600 ng/mL Tb4 significantly up-regulated AKT activity and Bcl-XL protein expression, enhanced dia-hiPSC-EC viability and proliferation, limited senescence, reduced endothelin-1 and MMP-1 secretion, and improved reparative potency of dia-hiPSC-ECs for treatment of ischemic limb disease in mice with T2DM.”

10 ng

rats ·

Transplantation of Endothelial Progenitor Cells in Obese Diabetic Rats Following Myocardial Infarction: Role of Thymosin Beta-4.Cells · 2020

“It was found that 10 ng/mL Tβ4 increased migration, tubule formation, and angiogenic factor secretion of diabetic EPCs in vitro.”